Anouk M Kesselring

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the Netherlands
    Anouk M Kesselring
    HIV Monitoring Foundation, Amsterdam, The Netherlands
    Antivir Ther 15:871-9. 2010
  2. doi request reprint Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy
    Anouk Kesselring
    HIV Monitoring Foundation, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Infect Dis 52:1458-65. 2011
  3. ncbi request reprint Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study
    Ferdinand W N M Wit
    Center for Poverty related Communicable Diseases, and Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Infect Dis 46:933-40. 2008
  4. doi request reprint Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy
    Anouk M Kesselring
    HIV Monitoring Foundation, The Netherlands
    AIDS 23:1689-99. 2009
  5. ncbi request reprint CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater
    Luuk Gras
    HIV Monitoring Foundation, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 45:183-92. 2007

Detail Information

Publications5

  1. ncbi request reprint Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the Netherlands
    Anouk M Kesselring
    HIV Monitoring Foundation, Amsterdam, The Netherlands
    Antivir Ther 15:871-9. 2010
    ..We investigated differences in immune restoration and onset of new AIDS-defining events on combination antiretroviral therapy (cART) among HIV type-1 (HIV-1)-infected patients of different regional origin now living in the Netherlands...
  2. doi request reprint Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy
    Anouk Kesselring
    HIV Monitoring Foundation, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Infect Dis 52:1458-65. 2011
    ..The aim of this study was to investigate the association between immunodeficiency, viremia, and non-AIDS-defining malignancies (NADM)...
  3. ncbi request reprint Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study
    Ferdinand W N M Wit
    Center for Poverty related Communicable Diseases, and Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Infect Dis 46:933-40. 2008
    ..It is unclear whether these guidelines also apply to treatment-experienced patients switching to NVP-based combination therapy...
  4. doi request reprint Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy
    Anouk M Kesselring
    HIV Monitoring Foundation, The Netherlands
    AIDS 23:1689-99. 2009
    ....
  5. ncbi request reprint CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater
    Luuk Gras
    HIV Monitoring Foundation, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 45:183-92. 2007
    ..CD4 cell count changes in therapy-naive patients were investigated during 7 years of highly active antiretroviral therapy (HAART) in an observational cohort...